MGI Launches Overseas Production Line of DNBSEQ-G400* Sequencer in Latvia

May 8, 2023

News

Latvia

Share

MGI Tech Co., Ltd. launches an overseas production line in Latvia to assemble the advanced DNBSEQ-G400* gene sequencing instruments and HotMPS** reagents, marking a significant milestone in MGI's expansion into the European market.
MGI Tech Co., Ltd. launches an overseas production line in Latvia to assemble the advanced DNBSEQ-G400* gene sequencing instruments and HotMPS** reagents, marking a significant milestone in MGI's expansion into the European market.

In a significant move that further solidifies its commitment to advancing life science technology, MGI Tech Co., Ltd. ("MGI") is proud to announce the launch of its overseas production line in Latvia. Under the subsidiary name LATVIA MGI TECH, SIA ("MGI Latvia"), the company has established a large-scale facility in Riga to assemble and produce the state-of-the-art DNBSEQ-G400* gene sequencing instruments and Sequencing reagents. This strategic expansion marks a significant milestone for MGI's growth in Europe, enabling the company to provide cutting-edge solutions for its customers and partners in the region.

MGI's Expansion in Europe

Europe has always been at the forefront of technology and innovation, making it a key market for MGI. By launching its production line in Latvia, MGI aims to leverage the region's technological prowess and establish a strong foothold in Europe's life science sector. The facility in Riga will serve as MGI's largest regional hub in Europe, enabling efficient production, assembly, and distribution of the DNBSEQ-G400* sequencers reagents.

A Milestone Achievement

During the official opening ceremony, MGI unveiled the first DNBSEQ-G400* instrument produced at the Latvia site. This momentous occasion represents a significant step forward for MGI's European business development. As the company gradually increases its production capacity, a dedicated team of engineers in Latvia will provide ongoing support for production and quality control. Additionally, MGI Latvia will offer comprehensive aftersales support and maintenance services to ensure the seamless operation of the sequencing instruments.

MGI Latvia's Contributions to Research and Development

Since its establishment in 2019, MGI Latvia has emerged as a dynamic hub for research and development, production, logistics, and specialized training. With a remarkable investment exceeding 20 million euros, MGI Latvia is the largest foreign investment in the biotechnology sector in Latvia and the Baltics to date. The facility spans 7,000 square meters and features a Global Product Application Demo Centre and a state-of-the-art Customer Experience Center, which opened last year to showcase MGI's latest technologies. In addition to production activities, MGI Latvia has successfully collaborated with local and regional partners on numerous funded research programs, including Horizon 2020.


DNBSEQ-G400

Sequencing

Share

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

Mar 4, 2024

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Nov 10, 2023

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Jul 10, 2023

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.